XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenue $ 12,728.5 $ 8,768.0
U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 8,489.4 5,694.4
Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,239.1 3,073.7
Cardiometabolic Health    
Disaggregation of Revenue [Line Items]    
Revenue 9,208.1 5,493.0
Cardiometabolic Health | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 6,576.7 4,090.0
Cardiometabolic Health | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,631.4 1,403.0
Mounjaro    
Disaggregation of Revenue [Line Items]    
Revenue 3,841.8 1,806.5
Mounjaro | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,655.9 1,520.4
Mounjaro | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,185.9 286.2
Zepbound    
Disaggregation of Revenue [Line Items]    
Revenue 2,311.9 517.4
Zepbound | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,305.4 517.4
Zepbound | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 6.5 0.0
Trulicity    
Disaggregation of Revenue [Line Items]    
Revenue 1,095.2 1,456.3
Trulicity | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 770.5 1,081.9
Trulicity | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 324.7 374.4
Jardiance    
Disaggregation of Revenue [Line Items]    
Revenue 1,014.4 686.5
Jardiance | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 309.8 368.2
Jardiance | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 704.6 318.3
Other cardiometabolic health    
Disaggregation of Revenue [Line Items]    
Revenue 944.8 1,026.3
Other cardiometabolic health | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 535.1 602.1
Other cardiometabolic health | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 409.7 424.1
Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 1,947.5 1,810.0
Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,045.8 998.3
Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 901.7 811.7
Verzenio    
Disaggregation of Revenue [Line Items]    
Revenue 1,158.9 1,050.3
Verzenio | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 657.6 638.2
Verzenio | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 501.3 412.1
Other oncology    
Disaggregation of Revenue [Line Items]    
Revenue 788.6 759.7
Other oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 388.2 360.1
Other oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 400.4 399.6
Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 1,088.0 834.0
Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 578.1 397.2
Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 510.0 436.8
Taltz    
Disaggregation of Revenue [Line Items]    
Revenue 761.9 604.1
Taltz | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 476.5 347.1
Taltz | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 285.4 257.0
Other immunology    
Disaggregation of Revenue [Line Items]    
Revenue 326.1 229.9
Other immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 101.6 50.1
Other immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 224.6 179.8
Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 272.1 389.1
Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 189.3 163.2
Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 82.8 225.9
Other    
Disaggregation of Revenue [Line Items]    
Revenue 212.9 241.9
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 99.5 45.7
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue $ 113.3 $ 196.2